GEN Exclusives

More »

GEN News Highlights

More »
Aug 7, 2007

Deal with Merck & Co. Could Be Worth over $700M to KineMed

  • KineMed has agreed to use its reverse cholesterol transport (RCT) technology to evaluate Merck & Co.’s investigational compounds. KineMed stands to earn up to $705.5 million based on various milestones.

    RCT is the only known metabolic pathway by which excess cholesterol can be removed from tissues, explain the companies. A relevant increase in the rate of RCT is the goal in raising HDL levels for the prevention and treatment of atherosclerosis.

    Under the terms of the agreement, KineMed could receive in excess of $5.5 million in initial and research payments should the collaboration extend for the full term. Merck will pay an additional $70 million in milestones for each of up to 10 compounds.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?